2025³â 09¿ù 22ÀÏ ¿ù¿äÀÏ
 
 
  ÇöÀçÀ§Ä¡ > ´º½ºÁö´åÄÄ > Science & Technology

·£¼¶¿þ¾îºÎÅÍ µÅÁöµµ»ì±îÁö... ³ë·ÃÇØÁø »ç±âÇà°¢

 

Á¤Ä¡

 

°æÁ¦

 

»çȸ

 

»ýȰ

 

¹®È­

 

±¹Á¦

 

°úÇбâ¼ú

 

¿¬¿¹

 

½ºÆ÷Ã÷

 

ÀÚµ¿Â÷

 

ºÎµ¿»ê

 

°æ¿µ

 

¿µ¾÷

 

¹Ìµð¾î

 

½Å»óǰ

 

±³À°

 

ÇÐȸ

 

½Å°£

 

°øÁö»çÇ×

 

Ä®·³

 

Ä·ÆäÀÎ
Çѻ츲 ¡®¿ì¸®´Â ÇѽҸ²¡¯ ½Ò ¼Òºñ Ä·ÆäÀÎ ½Ã...
1000¸¸¿øÂ¥¸® Àΰø¿Í¿ì, °Ç°­º¸Çè Áö¿ø ¡®Æò...
- - - - - - -
 

MSCI Advances Private Markets Strategy With New Solutions Built for General Partners

Private Asset and Deal Metrics and RCA Funds further demonstrate MSCI¡¯s commitment to empower GPs with purpose-built, scalable, data-driven tools
´º½ºÀÏÀÚ: 2025-08-08

NEW YORK -- MSCI Inc. (NYSE: MSCI) has launched two new data and analytics solutions, Private Asset and Deal Metrics and Real Capital Analytics (RCA) Funds, designed to provide General Partners (GPs) with deeper insights and enhanced investor engagement capabilities, enabling them to develop more effective strategies for capital formation and deployment across private asset and commercial real estate markets.

Private Asset and Deal Metrics is built on private company and deal-level data from more than 26,000 private equity buyout deals representing $2 trillion in net asset value[1]. The solution enables GPs to benchmark performance, validate investment themes and engage Limited Partners (LPs) with greater confidence.

RCA Funds delivers global intelligence on institutional real estate funds. It draws on commercial real estate profiles of over 1,600 GPs and 800 LPs and data on more than 8,000 real-estate funds[2]. The solution supports GPs’ fundraising by providing deep insights into LP investment criteria and also helps them strengthen investor relations through transparent fund performance for better reporting.

In the recent MSCI General Partner Survey, more than half of respondents said that they face difficulties finding attractive deals, while one third identified fundraising and capital flows as their top challenges. As GPs navigate this complex and increasingly competitive environment, these new solutions are designed to address critical gaps in data transparency, benchmarking and decision-making capabilities across the full capital investment lifecycle.

“GPs are operating under increasing pressure in what continues to be a challenging market environment, facing heightened competition for capital and deal-making as well as growing scrutiny from investors and regulators,” said Luke Flemmer, Head of Private Assets at MSCI. “Our goal is to deliver solutions that empower general partners to more clearly articulate their value, operate with greater efficiency and clarity and strengthen investor engagement. We are committed to building a robust suite of scalable tools, analytics and institutional-quality insights that drive client success and expand transparency across private markets.”

While MSCI continues to introduce innovative and tech-enabled solutions that serve the needs of all types of private market practitioners, these launches build on the firm’s ongoing commitment to supporting the GP community. These new solutions expand MSCI’s dedicated suite of products aimed at GPs, including Private Capital Intel, which allows clients to benchmark performance against one of the largest pools of private capital data with extensive coverage of historical profiles sourced directly from LPs, and the recent partnership with Intapp to deliver enhanced private capital market intelligence.

[1] As of Q2 2025
[2] As of Q2 2025



 Àüü´º½º¸ñ·ÏÀ¸·Î

The Open Group Launches the Industrial Advanced Nuclear¢â Consortium
IQM Quantum Computers Secures $300M in Series B Led by Ten Eleven Ventures With Backing From Tesi
UK Co-ops Transform Retail With SymphonyAI¡¯s AI-Powered Connected Retail Platform
Lenovo Unveils Full Portfolio of AI-Powered Devices and Experiences Across Consumer, Business, and Mobile
Black & Veatch Powers the Philippines¡¯ First Megawatt-Scale Floating Solar Facility
World's First Spatial Agentic Browser That Works While You Rest—Fellou CE Launches
Polpharma Biologics And MS Pharma Ink Licensing Deals For Proposed Vedolizumab, Ocrelizumab, And Guselkumab Biosimilars (PB016–PB019)

 

Stellantis Joins GlobalPlatform to Advance Global Automotive Cybersecu...
Deep Fission Nuclear Completes $30M Financing in a Go-Public Transacti...
Rigaku Launches XTRAIA XD-3300 Mass Production for Semiconductor Marke...
Biocytogen Enters into Agreement with Merck to Advance Antibody-Conjug...
Novotech Supports Groundbreaking Approval of Anlotinib Combination The...
Toshiba Releases 650V 3rd Generation SiC MOSFETs in TOLL Package
Montage Technology Introduces CXL¢ç 3.1 Memory eXpander Controller to ...

 


°øÁö»çÇ×
´º½ºÁö ÇÑÀÚ Ç¥±â¿¡ ´ë¸¸½Ä À½Â÷ Ç¥±â '纽ÞÙó¢ ´Ï¿ì½ÃÁö' º´±â
º£³×ÇÁ·Ò º£³×ÀÎÅõ Áß¹® Ç¥±â 宝Ò¬ÜØÙÌ 宝Ò¬ì×öõ(ÜÄÒ¬ÜØÙÌ ÜÄ...
¹Ìµð¾î¾Æ¿ì¾î Mediaour ØÚ体ä²们 ØÚô÷ä²Ùú MO ¿¥¿À ØÚä² ØÚä²
¾Ë¸®¿ìºê Alliuv ä¹备: ä¹联êó备, ¾Ë¶ã Althle ä¹÷åìÌ
¾Ë¸®¾Ë Allial Áß¹® Ç¥±â ä¹××尔 ä¹××ì³
´ºÆÛ½ºÆ® New1st Áß¹® Ç¥±â 纽ììãæ(¹øÃ¼ Òïììãæ), N1 纽1
¿£ÄÚ½º¸ð½º : À̾¾ 'EnCosmos : EC' Áß¹® Ç¥±â ì¤ñµ
¾ÆÀ̵ð¾î·Ð Idearon Áß¹® Ç¥±â ì¤îè论 ì¤îèÖå
¹ÙÀÌ¿ÀÀÌ´Ï Bioini Áß¹® Ç¥±â ù±药研 ù±å·æÚ
¿À½ºÇÁ·Ò Ausfrom 奥ÞÙÜØÙÌ, À£ÇÁ·Ò Welfrom 卫ÜØÙÌ
¿¡³ÊÇÁ·Ò Enerfrom 额ÒöÜØÙÌ ¿¡³ÊÀ¯ºñ Eneruv 额Òöêó备
¾ËÇÁ·Ò Alfrom Áß¹® Ç¥±â ä¹尔ÜØÙÌ ä¹ì³ÜØÙÌ

 

ȸ»ç¼Ò°³ | ÀÎÀçä¿ë | ÀÌ¿ë¾à°ü | °³ÀÎÁ¤º¸Ãë±Þ¹æÄ§ | û¼Ò³âº¸È£Á¤Ã¥ | Ã¥ÀÓÇѰè¿Í ¹ýÀû°íÁö | À̸ÞÀÏÁÖ¼Ò¹«´Ü¼öÁý°ÅºÎ | °í°´¼¾ÅÍ

±â»çÁ¦º¸ À̸ÞÀÏ news@newsji.com, ÀüÈ­ 050 2222 0002, ÆÑ½º 050 2222 0111, ÁÖ¼Ò : ¼­¿ï ±¸·Î±¸ °¡¸¶»ê·Î 27±æ 60 1-37È£

ÀÎÅͳݴº½º¼­ºñ½º»ç¾÷µî·Ï : ¼­¿ï ÀÚ00447, µî·ÏÀÏÀÚ : 2013.12.23., ´º½º¹è¿­ ¹× û¼Ò³âº¸È£ÀÇ Ã¥ÀÓ : ´ëÇ¥ CEO

Copyright ¨Ï All rights reserved..